TY  - JOUR
AU  - Becker, Jürgen
AU  - Lodde, Georg
AU  - Haist, Maximilian
AU  - Ugurel, Selma
TI  - Merkel cell carcinoma immunotherapy: key questions in the era of immune checkpoint blockade.
JO  - Journal for ImmunoTherapy of Cancer
VL  - 14
IS  - 1
SN  - 2051-1426
CY  - London
PB  - BioMed Central
M1  - DKFZ-2026-00104
SP  - e014090
PY  - 2026
N1  - #DKTKZFB26#
AB  - Merkel cell carcinoma (MCC) exemplifies the paradigm of immunogenic tumors that nonetheless develop sophisticated immune evasion mechanisms. This is in line with the observation that MCC exhibits remarkable susceptibility to immune checkpoint inhibitors (ICIs), with responses in approximately half of patients with advanced disease in the first-line setting. However, 40-50
KW  - Humans
KW  - Carcinoma, Merkel Cell: drug therapy
KW  - Carcinoma, Merkel Cell: immunology
KW  - Immune Checkpoint Inhibitors: therapeutic use
KW  - Immune Checkpoint Inhibitors: pharmacology
KW  - Immunotherapy: methods
KW  - Skin Neoplasms: drug therapy
KW  - Skin Neoplasms: immunology
KW  - Adjuvant (Other)
KW  - Biomarker (Other)
KW  - Immune Checkpoint Inhibitor (Other)
KW  - Immunotherapy (Other)
KW  - Neoadjuvant (Other)
KW  - Immune Checkpoint Inhibitors (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:41529910
DO  - DOI:10.1136/jitc-2025-014090
UR  - https://inrepo02.dkfz.de/record/307633
ER  -